NASDAQ:OCX OncoCyte (OCX) Stock Price, News & Analysis → Elon Musk’s Next Move Will Disrupt AI Forever (From InvestorPlace) (Ad) Free OCX Stock Alerts $2.90 +0.02 (+0.69%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$2.71▼$2.9150-Day Range$2.44▼$3.0752-Week Range$2.08▼$5.60Volume26,845 shsAverage Volume44,241 shsMarket Capitalization$23.98 millionP/E RatioN/ADividend YieldN/APrice Target$4.06 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get OncoCyte alerts: Email Address OncoCyte MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside40.1% Upside$4.06 Price TargetShort InterestBearish3.64% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.16Based on 5 Articles This WeekInsider TradingAcquiring Shares$7.18 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.78 out of 5 starsMedical Sector2001st out of 2,771 stocksDiagnostic Substances Industry25th out of 39 stocks 3.3 Analyst's Opinion Consensus RatingOncoCyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageOncoCyte has only been the subject of 3 research reports in the past 90 days.Read more about OncoCyte's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.64% of the float of OncoCyte has been sold short.Short Interest Ratio / Days to CoverOncoCyte has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in OncoCyte has recently increased by 60.53%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOncoCyte does not currently pay a dividend.Dividend GrowthOncoCyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OCX. Previous Next 2.9 News and Social Media Coverage News SentimentOncoCyte has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for OncoCyte this week, compared to 1 article on an average week.Search Interest11 people have searched for OCX on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.MarketBeat Follows2 people have added OncoCyte to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OncoCyte insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,176,400.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.94% of the stock of OncoCyte is held by insiders.Percentage Held by Institutions55.35% of the stock of OncoCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OncoCyte's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioOncoCyte has a P/B Ratio of 1.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about OncoCyte's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden FINISHED On June 13th?Thanks to Biden’s disgraceful leadership we now have sky-high inflation… unchecked immigration… rampant crime… and a “woke mob” hell bent on destroying the America you and I know and love. Biden’s days are numbered.Click here now to see his shocking evidence. About OncoCyte Stock (NASDAQ:OCX)OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.Read More OCX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OCX Stock News HeadlinesMay 7, 2024 | insidertrades.com3 Penny Stocks That Insiders Are Buying (OCX)April 16, 2024 | insidertrades.comOncoCyte Co. (NASDAQ:OCX) CEO Buys $10,000.50 in StockMay 14 at 6:12 PM | msn.comOncoCyte Q1 2024 Earnings PreviewMay 13 at 8:11 AM | finance.yahoo.comOncocyte to Announce First Quarter 2024 Financial ResultsMay 12 at 3:16 AM | americanbankingnews.comOncoCyte (NASDAQ:OCX) Now Covered by StockNews.comMay 7, 2024 | finance.yahoo.comPRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics MarketplaceMay 6, 2024 | americanbankingnews.comOncoCyte (NASDAQ:OCX) Now Covered by Analysts at StockNews.comApril 24, 2024 | markets.businessinsider.comStrong Future Outlook for OncoCyte: Buy Rating and Increased Price Target Amid Positive Partnerships and Financial EfficiencyApril 22, 2024 | msn.comBuffett Grabs More of This Stock, Plus Other Notable Insider BuyingApril 13, 2024 | seekingalpha.comOncoCyte Corporation (OCX) Q4 2023 Earnings Call TranscriptApril 13, 2024 | finance.yahoo.comQ4 2023 OncoCyte Corp Earnings CallApril 12, 2024 | investorplace.comOCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023April 12, 2024 | msn.comTop 3 Health Care Stocks That May Collapse In Q2April 12, 2024 | finanznachrichten.deOncoCyte Corporation: Oncocyte and Bio-Rad Partner on Global Launch of Transplant AssayApril 12, 2024 | msn.comS&P Futures Tick Lower as Investors Digest Big Bank EarningsApril 12, 2024 | msn.comS&P Futures Tick Lower as Investors Cautiously Await U.S. Big Bank EarningsApril 12, 2024 | msn.comOncocyte announces $15.8 mln private placement of securitiesApril 12, 2024 | globenewswire.comOncocyte Reports Full Year 2023 Financial ResultsApril 11, 2024 | globenewswire.comOncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq RulesApril 11, 2024 | globenewswire.comOncocyte and Bio-Rad Partner on Global Launch of Transplant AssayApril 11, 2024 | markets.businessinsider.comHere's what Wall Street expects from Oncocyte's earningsApril 9, 2024 | globenewswire.comOncocyte to Announce Fourth Quarter and Full Year 2024 Financial ResultsFebruary 29, 2024 | msn.comNeuroBo stock jumps 14% on weight-loss drug updateFebruary 24, 2024 | benzinga.comOncoCyte Stock (NASDAQ:OCX), Short Interest ReportJanuary 16, 2024 | finance.yahoo.comOncocyte to Present at the Sequire Investor Summit in Puerto RicoSee More Headlines Receive OCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today5/14/2024Next Earnings (Confirmed)5/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:OCX CUSIPN/A CIK1642380 Weboncocyte.com Phone(949) 409-7600Fax510-521-3389Employees75Year FoundedN/APrice Target and Rating Average Stock Price Target$4.06 High Stock Price Target$5.00 Low Stock Price Target$3.00 Potential Upside/Downside+40.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,780,000.00 Net Margins-1,890.62% Pretax Margin-1,653.69% Return on Equity-96.30% Return on Assets-41.12% Debt Debt-to-Equity RatioN/A Current Ratio1.49 Quick Ratio1.49 Sales & Book Value Annual Sales$1.50 million Price / Sales15.99 Cash FlowN/A Price / Cash FlowN/A Book Value$2.48 per share Price / Book1.17Miscellaneous Outstanding Shares8,270,000Free Float8,113,000Market Cap$23.98 million OptionableNo Data Beta0.80 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Joshua Riggs (Age 41)President, CEO & Director Comp: $373.2kMr. James Liu (Age 28)Senior Director, Controller, Principal Accounting Officer & Interim Principal Financial Officer Comp: $192.48kDr. Ekkehard Schutz M.D.Ph.D., Chief Science OfficerMr. Peter HongVP, General Counsel & SecretaryMr. Yuh-Min Chiang Ph.D.Senior Vice President of R&D and Product DevelopmentMs. Sandra O'DonaldSenior Vice President of Business OperationsDr. Michael D. West Ph.D. (Age 71)Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc. Ms. Sara RiordanDirector of Medical EducationMore ExecutivesKey CompetitorsCardio DiagnosticsNASDAQ:CDIOTrinity BiotechNASDAQ:TRIBAchilles TherapeuticsNASDAQ:ACHLBiomericaNASDAQ:BMRAAspira Women's HealthNASDAQ:AWHView All CompetitorsInsidersBroadwood Partners, L.P.Bought 2,420,000 shares on 4/11/2024Total: $7.07 M ($2.92/share)Andrew ArnoBought 33,898 shares on 4/11/2024Total: $99,999.10 ($2.95/share)Josh RiggsBought 3,390 shares on 4/11/2024Total: $10,000.50 ($2.95/share)Alfred D KingsleyBought 1,500 shares on 6/14/2023Total: $6,300.00 ($4.20/share)View All Insider Transactions OCX Stock Analysis - Frequently Asked Questions Should I buy or sell OncoCyte stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OCX shares. View OCX analyst ratings or view top-rated stocks. What is OncoCyte's stock price target for 2024? 4 Wall Street research analysts have issued 12-month price targets for OncoCyte's shares. Their OCX share price targets range from $3.00 to $5.00. On average, they predict the company's stock price to reach $4.06 in the next year. This suggests a possible upside of 40.1% from the stock's current price. View analysts price targets for OCX or view top-rated stocks among Wall Street analysts. How have OCX shares performed in 2024? OncoCyte's stock was trading at $2.50 at the start of the year. Since then, OCX shares have increased by 16.0% and is now trading at $2.90. View the best growth stocks for 2024 here. When is OncoCyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 15th 2024. View our OCX earnings forecast. How can I listen to OncoCyte's earnings call? OncoCyte will be holding an earnings conference call on Wednesday, May 15th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 646-307-1963 with passcode "4153469". How were OncoCyte's earnings last quarter? OncoCyte Co. (NASDAQ:OCX) announced its earnings results on Tuesday, November, 9th. The company reported ($3.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.40) by $0.60. The company had revenue of $0.98 million for the quarter, compared to analyst estimates of $3.20 million. OncoCyte had a negative net margin of 1,890.62% and a negative trailing twelve-month return on equity of 96.30%. When did OncoCyte's stock split? OncoCyte shares reverse split on Tuesday, July 25th 2023. The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of OncoCyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include VBI Vaccines (VBIV), Biocept (BIOC), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC), Xeris Biopharma (XERS), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Acasti Pharma (ACST) and Aileron Therapeutics (ALRN). How do I buy shares of OncoCyte? Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OCX) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressElon to Transform U.S. Economy? Porter & CompanyThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.